Education
About Us
Working with TipRanks
Follow Us
Azenta (AZTA)
NASDAQ:AZTA
Top Page
Azenta
(NASDAQ:AZTA)
Select Model
Select Model
Rating:61Neutral
Price Target:
$39.00
▲(11.27% Upside)
Azenta's overall stock score reflects a mix of strengths and challenges. The company's strong technical momentum and strategic share repurchase program are positive factors. However, financial performance issues, particularly in profitability and valuation, weigh on the score. The earnings call provided a cautiously optimistic outlook, but macroeconomic challenges remain a concern.
Azenta (AZTA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.58B
Dividend YieldN/A
Average Volume (3M)587.59K
Price to Earnings (P/E)―
Beta (1Y)0.84
Revenue Growth-9.49%
EPS Growth58.97%
CountryUS
Employees3,000
SectorN/A
Sector StrengthN/A
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.21
Shares Outstanding45,989,285
10 Day Avg. Volume463,449
30 Day Avg. Volume587,594
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)0.76
Price to Sales (P/S)2.21
P/FCF Ratio34.28
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue1.92
Enterprise Value/Gross Profit4.15
Enterprise Value/Ebitda26.25
Forecast
1Y Price Target
$38.33Price Target Upside9.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Azenta Business Overview & Revenue Model
Company DescriptionAzenta (AZTA) is a leading provider of life sciences solutions, specializing in sample management and genomic services. The company operates primarily in the biotechnology and pharmaceutical sectors, offering a range of services that include biobanking, sample storage, and genomic analysis. Azenta's core products and services are designed to support researchers and organizations in advancing their scientific endeavors, particularly in drug development and personalized medicine.
How the Company Makes MoneyAzenta generates revenue through multiple streams, primarily from its biobanking and genomic services. The company charges clients for sample storage, management, and processing, which are essential for research and clinical trials. Additionally, Azenta offers genomic analysis services, including sequencing and data interpretation, which are crucial for clients engaged in genetic research and diagnostics. Significant partnerships with pharmaceutical companies, research institutions, and academic organizations enhance its revenue generation, as these collaborations often lead to long-term contracts and increased service utilization. Furthermore, Azenta's expansion into international markets and investment in cutting-edge technologies contribute to its growth and profitability.
Azenta Earnings Call Summary
Earnings Call Date:Nov 21, 2025
(Q4-2025)
| % Change Since: |
Next Earnings Date:Feb 11, 2026
Earnings Call Sentiment Neutral
Azenta, Inc. demonstrated resilience amidst a challenging macroeconomic environment, achieving revenue growth and margin expansion. The company reported record performance in its Multiomics segment and maintained a strong cash position. However, macroeconomic challenges and specific segment weaknesses, such as in Sanger sequencing and automated storage, were notable concerns. The company remains optimistic about its growth prospects in fiscal 2026, with anticipated revenue growth and margin expansion.Q4-2025 Updates
Positive Updates
Revenue Growth and Margin Expansion
Fourth-quarter revenue was $159 million, up 6% year over year on a reported basis and up 4% organically. Fiscal year 2025 revenue was $594 million, up 4% on a reported basis and up 3% organically. Adjusted EBITDA margin expanded by 310 basis points for the full year.
Record Performance in Multiomics
Multiomics delivered record revenue of $73 million in the quarter, representing 11% growth on a reported basis and 10% organic growth. Sequence volume rose 50% year over year.
Strong Cash Position
The company ended the year with $546 million in cash, cash equivalents, and marketable securities, providing flexibility for growth investment and shareholder returns.
Positive Outlook for Fiscal 2026
Anticipated core revenue growth between 3% to 5% and expected adjusted EBITDA margin expansion of 300 basis points in fiscal 2026, with higher free cash flow generation.
Negative Updates
Impact of Macroeconomic Challenges
The macroeconomic environment was characterized by softer academic and NIH funding, shifting biopharma priorities, and geopolitical uncertainty, impacting customer capital expenditure decisions.
Sanger Sequencing Revenue Decline
Sanger sequencing revenue declined by low double-digit percentages year over year, consistent with trends discussed in prior quarters.
Challenges in Automated Storage
Slower bookings in cryogenic stores due to ongoing customer budget constraints and macroeconomic uncertainty, affecting capital expenditures.
Company Guidance
In the recent Azenta, Inc. Q4 2025 earnings call, the company provided guidance for fiscal year 2026, anticipating core revenue growth between 3% to 5% and projecting adjusted EBITDA margin expansion of 300 basis points. Azenta expects higher free cash flow generation as they scale operational improvements, with a continued focus on driving productivity, accelerating organic growth, and optimizing capital deployment. The company's balance sheet remains robust, with over $546 million in cash, cash equivalents, and marketable securities, positioning them well to invest in growth initiatives, including potential tuck-in M&A. Despite macroeconomic uncertainties, including capital spending slowdowns and impacts from a government shutdown, Azenta maintains its commitment to operational excellence and value creation, supported by strategic investments in innovation and commercial capabilities.Azenta Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
60
Neutral
Cash Flow
50
Neutral
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Azenta Technical Analysis
Positive
35.05
Price Trends
32.68
Positive
31.45
Positive
31.06
Positive
Market Momentum
0.60
Positive
52.87
Neutral
15.79
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AZTA, the sentiment is Positive. The current price of 35.05 is below the 20-day moving average (MA) of 35.50, above the 50-day MA of 32.68, and above the 200-day MA of 31.06, indicating a neutral trend. The MACD of 0.60 indicates Positive momentum. The RSI at 52.87 is Neutral, neither overbought nor oversold. The STOCH value of 15.79 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AZTA.
Azenta Peers Comparison
UnderperformOutperform
Sector (―)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | ― | ― | ― | ― | ― | ― | |
71 Outperform | $2.04B | -68.50 | -6.11% | ― | 15.80% | 26.94% | |
61 Neutral | $1.58B | -28.33 | 1.41% | ― | -9.49% | 58.97% | |
54 Neutral | $1.97B | -1.75 | -44.21% | ― | -3.43% | 38.98% | |
52 Neutral | $1.21B | -370.74 | -5.20% | ― | -18.82% | 92.56% | |
46 Neutral | $1.25B | -12.37 | -24.65% | ― | -32.42% | -540.37% | |
42 Neutral | $216.33M | -5.77 | -27.19% | ― | 30.55% | -340.19% |
* Sector Average
AZTA
Azenta
34.69
-15.56
-30.97%
ATRC
Atricure
41.65
11.15
36.56%
QDEL
QuidelOrtho
29.81
-14.77
-33.13%
STAA
Staar Surgical
24.20
-0.77
-3.08%
BLFS
BioLife Solutions
25.47
-1.03
-3.89%
SMTI
Sanara MedTech
25.04
-9.90
-28.33%
Azenta Corporate Events
Stock BuybackBusiness Operations and Strategy
Azenta Announces $250 Million Share Repurchase Program
Positive
Dec 10, 2025
On December 10, 2025, Azenta, Inc. announced a $250 million share repurchase program authorized by its Board of Directors, effective from December 9, 2025, to December 31, 2028. The program aims to enhance shareholder value and capitalize on stock undervaluation, with repurchases occurring through various compliant methods based on market conditions and other factors. This strategic move is part of Azenta’s capital allocation strategy, which focuses on productivity, organic growth, strategic mergers and acquisitions, and returning capital to shareholders.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.